(Q37504690)

20 August 2017

1 reference

title

Peptide-receptor radionuclide therapy for endocrine tumors (English)

1 reference

20 August 2017

6

Dik J Kwekkeboom

1 reference

20 August 2017

2

Eric P Krenning

1 reference

20 August 2017

3

Boen L R Kam

1 reference

20 August 2017

1

Martijn van Essen

1 reference

20 August 2017

5

Roelf Valkema

1 reference

20 August 2017

Marion de Jong

4

1 reference

20 August 2017

publication date

2 June 2009

1 reference

Nature Reviews Endocrinology

20 August 2017

published in

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

382-393

1 reference

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Chemotherapy for gastro-enteropancreatic endocrine tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2009.105

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

31 March 2020

1 reference

12 December 2020

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

1 reference

12 December 2020

Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors

1 reference

12 December 2020

Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma

1 reference

12 December 2020

Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma

1 reference

12 December 2020

Anticancer activity of targeted proapoptotic peptides.

1 reference

12 December 2020

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides.

1 reference

12 December 2020

Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.

1 reference

12 December 2020

Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog.

1 reference

12 December 2020

A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer

1 reference

12 December 2020

Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.

1 reference

12 December 2020

Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2009.105

1 reference

20 August 2017

1 reference